Lurasidone
SGA • Last reviewed 2025-09-23
Brands: Latuda
Sources updated 2025 • 1 references
General Information
Indicated for: Schizophrenia; bipolar depression (monotherapy or adjunct to lithium/valproate). Second‑generation antipsychotic (SGA)
Dosage & Administration
Typical dose range: 40–160 mg/day (with food)
Indications (label)
Schizophrenia; bipolar depression (monotherapy or adjunct to lithium/valproate).
View labelExact
Mechanism (brief)
D2 and 5‑HT2A antagonism; 5‑HT7 antagonism; 5‑HT1A partial agonism.
Metabolism & Half‑life
- Metabolism: CYP3A4 substrate; avoid strong inhibitors/inducers.
- Half‑life: ~18 h.
Therapeutic Drug Monitoring (TDM)
Recommended: No
References
- Lurasidone labelExact (2025)
- Comparative efficacy and tolerability of pharmacological interventions for acute bipolar depression in adults: a network meta-analysis. — The Lancet Psychiatry (2023)
- Lurasidone in bipolar depression: meta‑analysis — Meta‑analysis (2020)